Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06916065 · ClinicalTrials.gov registry record · Phase 1
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 188
- Enrollment target
NCT06916065 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 188 participants.
The verdict
NCT06916065, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 188 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much eloralintide and eloralintide with tirzepatide get into the bloodstream and how long it takes the body to eliminate it. There will be 6 cohorts. The study will last up to approximately 26 weeks, excluding screening for Cohorts A and B, 11 weeks for Cohorts C and D, and 12 weeks for Cohorts E and F.
Interventions
- DRUG Eloralintide
- DRUG Eloralintide and Tirzepatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2025-04-09 |
| Est. Completion | 2026-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06916065
The ClinicalTrials.gov registry entry for NCT06916065 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eloralintide is the first listed.
NCT06916065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06916065 about?
NCT06916065 is a clinical study titled "A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity". The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check h...
What is the current status of trial NCT06916065?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 188 participants. The study started on 2025-04-09. Estimated completion is 2026-01-19.
What interventions are being tested in trial NCT06916065?
The interventions under investigation include: Eloralintide (DRUG), Eloralintide and Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06916065?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.